Immunosuppressive therapy with antithymocyte globulin and cyclosporine for prolonged marrow failure after hemophagocytic syndrome

Ann Hematol. 2003 Nov;82(11):699-701. doi: 10.1007/s00277-003-0714-1. Epub 2003 Sep 5.

Abstract

We describe a patient with typical hemophagocytic syndrome (HPS) in whom pancytopenia was refractory to steroid pulse therapy. He was successfully treated with immunosuppressive therapy using antithymocyte globulin (ATG) and cyclosporine (CyA), which is known to be effective for aplastic anemia (AA). Activation of histiocytes occurs in HPS as a response to several cytokines produced by activated T lymphocytes, while apoptosis of hematopoietic stem cells in AA is caused by T lymphocyte-derived cytokines. The response of this patient indicated that both diseases may have some similar immune-mediated conditions involving the activation of T lymphocytes and that intensive immunosuppressive therapy with ATG and CyA might be a useful strategy for steroid-resistant HPS.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antilymphocyte Serum / therapeutic use*
  • Cyclosporine / therapeutic use*
  • Hemoglobins / metabolism
  • Histiocytosis, Non-Langerhans-Cell / blood
  • Histiocytosis, Non-Langerhans-Cell / complications*
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Leukocyte Count
  • Male
  • Methylprednisolone / therapeutic use
  • Pancytopenia / blood
  • Pancytopenia / drug therapy*
  • Pancytopenia / etiology*
  • Platelet Count
  • Reticulocyte Count
  • Treatment Outcome

Substances

  • Antilymphocyte Serum
  • Hemoglobins
  • Immunosuppressive Agents
  • Cyclosporine
  • Methylprednisolone